HomeTrialNCT07379827
🔬NCT07379827RECRUITING

Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)

Study Summary

The purpose of this study is to describe real-world treatment patterns, effectiveness and adverse events of adults diagnosed with schizophrenia that have initiated xanomeline and trospium chloride (KarXT) treatment in the United States

Conditions
View on ClinicalTrials.gov ↗
Study Details
Enrollment1500 participants
Primary Completion
Lead SponsorBristol-Myers Squibb
Data Retrieved2026-04-11 04:08:14.745720+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.